Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
163 Leser
Artikel bewerten:
(1)

Apollo Cancer Centres: Apollo Cancer Centre in Navi Mumbai Advances Cancer Care with 2 Successful CAR T-Cell Therapies

MUMBAI, India, Sept. 4, 2025 /PRNewswire/ -- Apollo Cancer Centre (ACC), Navi Mumbai, has successfully treated 2 patients with made-in-India CAR T-cell therapy. This ground-breaking immunotherapy used patients' own genetically modified immune cells to target and destroy cancer.

L to R - Dr Vipin Khandelwal - Consultant Paediatric Hemato Oncology & BMT Apollo Cancer Centre, Navi Mumbai, Mr Arunesh Punetha - Regional CEO Apollo Cancer Centre, Western Region, Dr Punit Jain - Consultant Hematology, Hemato Oncology & Program Coordinator BMT & CAR T-cell Therapy, Apollo Cancer Centre, Navi Mumbai, Dr Kiran Shingote - Unit Head, Apollo Cancer Centre, Navi Mumbai, Dr Ravi Shankar - Director Medical Services, Apollo Cancer Centre, Navi Mumbai, Mr Sharma - Patient relative, Dr Dipali Patil - Consultant Blood Bank

ACC has seen remarkable success with 85 Bone Marrow Transplant (BMT) procedures with a long-term success rate of over 70%, successfully treating both adult and pediatric patients, including international cases. The recent CAR T-cell procedures highlight the hospital's commitment to delivering high-quality, life-saving transplant services.

Mrs. Sharma (49 yrs) from Odisha, was fighting blood cancer called B-cell acute lymphoblastic leukemia. Her immune cells (called T-cells) were extracted & re-engineered in the ImmunoACT lab so that they express modified connectors on their surface called Chimeric Antigen Receptors (CARs) to better recognize and attack her cancer. Before receiving the infusion, she received a course of chemotherapy to help the modified cells work effectively. CAR T-cell therapy was administered to her in May 2025. She was treated for fever & low blood cell counts after the therapy. She steadily improved and was discharged after a few weeks.

The 2nd patient, Mr. Das(57 yrs) from Mumbai, was diagnosed with follicular lymphoma, a type of blood cancer that had relapsed after several treatments including chemotherapy and radiation. His own immune cells (called T-cells) were collected and modified similarly & the CAR T-cell therapy was administered in June 2025. Although he developed a fever, his condition settled with medications & he was discharged a few weeks later.

Dr Punit Jain, Sr Consultant, Hemato Oncology & Program Co-ordinator BMT & CAR T-cell Therapy, ACC, Navi Mumbai, said, "CAR T-cell therapy is rewriting what's possible for patients with blood cancers who have relapsed on conventional treatment. This therapy offers hope for a complete cure in patients with aggressive or treatment-resistant cancers. We have been successfully performing challenging high-risk bone marrow transplants & are confident of providing advanced, evidence-based treatments to patients who undergo CAR T-cell procedures."

Mr. Arunesh Punetha, Regional CEO - Western Region, Apollo Hospitals, said, "The successful CAR -T cell cases at ACC are an example of our commitment to offer advanced cancer care available in India today. We have successfully performed CAR T-cell procedures in several other ACCs & this speaks volumes about our capability to deliver patient care of the highest standard."

Visit us at - https://apollocancercentres.com/

Photo: https://mma.prnewswire.com/media/2764505/Apollo_Cancer_Centre_Team.jpg
Logo: https://mma.prnewswire.com/media/2324542/4508246/Apollo_Cancer_Centers_Logo.jpg

Apollo Cancer Centers Logo (PRNewsfoto/Apollo Cancer Centers)

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/apollo-cancer-centre-in-navi-mumbai-advances-cancer-care-with-2-successful-car-t-cell-therapies-302546481.html

© 2025 PR Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.